BofA Securities has upgraded Tyra Biosciences, a clinical-stage biotech company, from Neutral to Buy, citing promising preclinical data for their drug TYRA-300 and its potential to treat urothelial carcinoma. The upgrade comes ahead of the presentation of phase 1/2 data at the ENA Meeting next week. BofA’s bullish outlook is based on the drug’s differentiated safety profile compared to existing treatments, leading to projected sales of $175 million by 2030.